The American Journal of Managed Care

BRVO, CRVO Need More Effective Long-term Therapies

While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, ...
The American Journal of Managed Care

Visual Acuity, Retinal Sensitivity Improved With Intravitreal Ranibizumab Injection

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...
Medscape

More Anti-VEGF Injections Might Increase Visual Acuity

STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...
Seeking Alpha

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
EurekAlert!

The hidden metabolic story behind vision-saving treatment

Overview of study design and analytical flow for identifying metabolic features associated with anti-VEGF therapy on macular edema (ME) patients (created with BioRender.com). anti-VEGF, anti-vascular ...